RORgamma modulators and uses thereof

Patent metadata

Field	Value
Publication number	US-11160801-B2
Application number	US-201816481172-A
Country	US
Kind code	B2
Filing date	Jan 29, 2018
Priority date	Jan 27, 2017
Publication date	Nov 2, 2021
Grant date	Nov 2, 2021

Abstract

The present invention provides novel compounds that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

First claim

The invention claimed is:

1. A compound of formula (I)

in which,
R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, an amino group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, or a heterocyclic group;
R1b is a hydrogen atom, a (C1-C6)alkyloxy group, a (C1-C6)alkyl group or a heterocyclic group;
R1c is a hydrogen atom, a halogen atom, a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, a heterocyclic group, a cyano group, an amido group or a hydroxyl group;
R1d and R1e are, independently, a hydrogen atom, a halogen atom, a (C1-C6)alkyloxy group or a (C1-C6)alkyl group;
wherein at least one R1a, R1b, R1c, R1d, and R1e is not a hydrogen atom;
R2 is a (C1-C6)alkyl group optionally substituted by a (C1-C6)alkyl group, a (C2-C6)alkenyl group optionally substituted by a (C1-C6)alkyl group, a (C2-C6)alkynyl group optionally substituted by a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group optionally substituted by a (C1-C6)alkyl group, a (C6-C14)aryl group optionally substituted by a (C1-C6)alkyl group or a heterocyclic group optionally substituted by a (C1-C6)alkyl group;
R′2 is a hydrogen atom, a (C1-C6)alkyl group, a (C2-C6)alkenyl group, a (C2-C6)alkynyl group, a (C3-C14)cycloalkyl group, a (C6-C14)aryl group optionally substituted by a (C1-C6)alkyl group or a heterocyclic group optionally substituted by a (C1-C6)alkyl group;
or R2 and R′2 can form, together with the carbon atom to which they are attached, a cycloalkyl group or a heterocycloalkyl group;
L1 is a NR7-CO—CH2, NR7-CO—, NR7-CO—C(CH3)2, CO—NH—CH2, CO—NH or CO—NH—C(CH3)2 group;
R7 is a hydrogen atom or a (C1-C6)alkyl group;
L2 represents a bond, a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group or a CR8R′8 group;
with the proviso that when L1 is a NR3-CO— or a CO—NH group, L2 represents a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group, or a CR8R′8 group;
R8 and R′8 are independently, a hydrogen atom, or a (C1-C6)alkyl group;
R8 and R′8 can optionally form, together with the carbon atom to which they are attached, a cycloalkyl group;
X1, X2, X3, X4 and X5 are, independently, a CH group, a C—R4 group, a C—X6 group or a nitrogen atom;
wherein one and only one of X1, X2, X3, X4, and X5 is a nitrogen atom;
X6 and X7 are independently a CH group or a nitrogen atom;
R3 is a hydrogen atom, a carbonyl(C1-C6)alkyl group, a SO2R′ group, a COOR′ group, an amido group, a (C1-C6)alkylamido group, or a (C1-C6)dialkylamido group;
R′ is a (C1-C6)alkyl group; and
R4 is a hydrogen atom, a (C1-C6)alkyl group, or a halogen atom.

2. The compound according to claim 1 , wherein:
R1a is a hydrogen atom, a halogen atom, a nitrile group, a nitro group (NO2), a (C1-C6)alkyl group, a (C1-C6)alkyloxy group, a (C1-C6)alkylthio group, an amino group, a (C1-C6)alkylamino group, a (C1-C6)dialkylamino group, a piperidinyl group, a pyrrolidinyl group, or an azepanyl group, wherein said piperidinyl, pyrrolidinyl or azepanyl group can be optionally substituted by at least one (C1-C6)alkyl groups;
R1b is a hydrogen atom;
R1c is a (C1-C6)alkyl group; and
R2 is a (C1-C6)alkyl group, a (C3-C14)cycloalkyl group, an (C6-C14)aryl group, or a heteroaryl group, and R′2 is a hydrogen atom.

3. The compound according to claim 1 , wherein X6 is a nitrogen atom and X7 is a CH group.

4. The compound according to claim 1 , wherein L1 is a NR7-CO—CH2, NR7-CO—C(CH3)2, CO—NH—CH2, or CO—NH—C(CH3)2 group and L2 is a bond.

5. The compound according to claim 1 , wherein L1 is a NR7-CO—, or —CO—NH— group and L2 is a cyclopropyl group of formula (III)

6. The compound according to claim 1 , wherein R1b is a hydrogen atom.

7. The compound according to claim 1 , wherein R1d and R1e are hydrogen atoms.

8. The compound according to claim 1 , wherein
R1a is a heterocyclic group,
R1c is a (C1-C6)alkyl group,
R2 is a heterocyclic group,
L1 represents a NH—CO—CH2 group,
L2 is a bound,
the cycle is in para or meta position of the L group,
X6 is a nitrogen atom and X7 is a CH group,
R3 represents a hydrogen atom, a carbonyl(C1-C6)alkyl group, a SO2R′ group, or a COOR′ group.

9. A compound selected from the group consisting of:
2-[6-(4-methanesulfonylpiperazin-1-yl)pyridin-3-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[6-(4-methanesulfonylpiperidin-1-yl)pyridin-3-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
tert-butyl 4-{5-[({[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}carbamoyl)methyl]pyridin-2-yl}piperazine-1-carboxylate;
2-[2-(4-methanesulfonylpiperazin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[2-(4-methanesulfonylpiperidin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[2-(4-acetylpiperidin-1-yl)pyrimidin-5-yl]-N-[(2,4-dimethylphenyl)(5-methylfuran-2-yl)methyl]acetamide;
methyl 1-{5-[({[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}carbamoyl)methyl]pyrimidin-2-yl}piperidine-4-carboxylate;
2-[2-(4-acetylpiperidin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
1-{5-[({[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}carbamoyl)methyl]pyrimidin-2-yl}piperidine-4-carboxylic acid;
N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}-2-[6-(piperazin-1-yl)pyridin-3-yl]acetamide;
1-[2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}cyclopropane-1-carboxamide;
2-[6-(4-acetylpiperazin-1-yl)pyridin-2-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[2-(4-acetylpiperazin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[5-(4-acetylpiperazin-1-yl)pyridin-3-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
2-[2-(4-acetylpiperazin-1-yl)pyrimidin-4-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide;
N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}-2-{6-[4-(trifluoroacetyl)piperazin-1-yl]pyridin-2-yl}acetamide; and
2-[2-(3-methanesulfonylpiperidin-1-yl)pyrimidin-5-yl]-N-{[4-methyl-2-(piperidin-1-yl)phenyl](5-methylfuran-2-yl)methyl}acetamide.

10. A combination product comprising:
i) a compound of formula (I) as defined in claim 1 , or a pharmaceutically acceptable salt thereof; and
ii) another therapeutically active agent, which is a PPAR activator.

11. The combination product according to claim 10 , wherein component ii) is elafibranor, seladelpar, saroglitazar, lanifibranor, pioglitazone, or a pharmaceutically acceptable salt thereof.

12. The combination product according to claim 10 , wherein the combination product is a composition comprising components i) and ii) and a pharmaceutically acceptable carrier.

13. The combination product according to claim 10 , wherein the combination product is a kit of parts comprising components i) and ii), for sequential, separate or simultaneous use.

14. The combination product according to claim 10 , wherein components i) and ii) are formulated in an injectable

Assignees

• Genfit

Inventors

• Delhomel Jean-Francois
• Perspicace Enrico
• Majd Zouher
• Parroche Peggy
• Walczak Robert
• Bonnet Pascal
• Fogha Jade

Classifications

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K31/40

  having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title

• C07D405/14 Primary

  containing three or more hetero rings · CPC title

• A61K31/4439

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title